Introduction: Icosapent ethyl (IPE) is indicated for the treatment of severe hypertriglyceridemia (triglycerides ≥500 mg/dl) and for reducing the risk of cardiovascular (CV) events in statin-treated ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of ...

The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for ...

The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for ...

The just-published final technology appraisal document recommends that Vazkepa (icosapent ethyl) can be prescribed to people in England and Wales for adult patients with high-risk cardiovascular ...

VASCEPA (icosapent ethyl) is indicated to reduce cardiovascular risk in patients with elevated triglyceride levels and established cardiovascular disease. Disclaimer: This is an AI-generated ...

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...